Discounted Cash Flow
Niagen Bioscience, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $26.8m | $-2.9m | $-4.4m | -10.9% | $-0.03 |
| 2017 | $21.2m (-20.9%) | $-11.4m (-288.6%) | $-11.0m (-147.0%) | -53.7% (-391.4%) | $-0.26 (-766.7%) |
| 2018 | $31.6m (48.8%) | $-33.3m (-192.8%) | $-22.2m (-102.6%) | -105.6% (-96.7%) | $-0.61 (-134.6%) |
| 2019 | $46.3m (46.7%) | $-32.1m (3.5%) | $-21.2m (4.7%) | -69.4% (34.2%) | $-0.56 (8.2%) |
| 2020 | $59.3m (28.0%) | $-19.9m (38.0%) | $-10.6m (49.7%) | -33.6% (51.6%) | $-0.33 (41.1%) |
| 2021 | $67.4m (13.8%) | $-27.1m (-36.2%) | $-24.2m (-126.9%) | -40.2% (-19.6%) | $-0.40 (-21.2%) |
| 2022 | $72.0m (6.8%) | $-16.5m (39.0%) | $-15.4m (36.1%) | -23.0% (42.9%) | $-0.24 (40.0%) |
| 2023 | $83.6m (16.0%) | $-4.9m (70.1%) | $7.0m (145.2%) | -5.9% (74.3%) | $-0.07 (70.8%) |
| 2024 | $99.6m (19.2%) | $8.6m (273.1%) | $11.9m (71.4%) | 8.6% (245.3%) | $0.11 (257.1%) |
| 2025 | $129.4m (29.9%) | $17.4m (103.3%) | $13.2m (10.6%) | 13.4% (56.4%) | $0.22 (100.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.